0.81
-3.61%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Akanda
Its shares trade under the ticker AKAN. It has been listed since 15 March 2022. In the fiscal year to 31 December 2024, it reported revenue of $836,664 and a net loss of $4.1m. At that date it held total assets of $7.9m and shareholders' equity of $4.3m.
Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which provides premium quality and ethically sourced medical cannabis products to patients worldwide. The firm operates through three segments: cultivation, distribution, and corporate. The cultivation segment is focused on the cultivation of medical cannabis and medical cannabis biomass respectively. The distribution segment undertakes the sale and distribution of medical cannabis products. Its portfolio includes Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a United Kingdom-based fully licensed pharmaceutical importer and distributor, which supplies pharmacies and clinics within the United Kingdom. Holigen consists of a 20,000 square foot indoor facility located near Lisbon (in Sintra) dedicated to the cultivation of high-tetrahydrocannabinol (THC) cannabis. The Company’s seed-to-patient supply chain includes Cansativa Group, an importer and distributor of medical cannabis in Europe, and Cellen Life Sciences Leva Clinic, which is a fully digital pain clinic in the United Kingdom.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Mar 2022
- Employees
- 46
- Website
- akandacorp.com ↗
- Head office
- 1A, 1B LEAROYD ROAD, NEW ROMNEY, X0, TN28 8XU
- Incorporated in
- A6
- Classification
- Communications Services, NEC
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Ms. Katharyn FieldChief Executive Officer, Executive Director, since 2022$96,000
- Mr. Gurcharn DeolChief Financial Officer$3,407
- Mr. Christopher CooperDirector$20,000
- Mr. Usama ChaudhryIndependent Director
- Mr. Jatinder DhaliwalIndependent Director$96,000
- Mr. David JenkinsIndependent Director$96,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Akanda Corp. operates a seed-to-patient supply chain with Cansativa Group and Cellen Life Sciences Leva Clinic.
- Holigen's 20,000 square foot indoor facility near Lisbon cultivates high-THC cannabis.
- CanMart supplies pharmacies and clinics across the United Kingdom as a fully licensed distributor.
Weaknesses
- Akanda Corp. has only 46 employees, which may limit operational capacity.
- The company's distribution segment relies on a single UK-based distributor, CanMart.
- Holigen's facility in Sintra is limited to high-THC cannabis cultivation.
Opportunities
- Expanding Holigen's facility near Lisbon could increase high-THC cannabis production.
- The UK market offers growth potential for CanMart's pharmaceutical distribution services.
- Cansativa Group's European import and distribution network supports international expansion.
Threats
- Regulatory changes in the UK could impact CanMart's pharmaceutical distribution operations.
- The cannabis industry faces strict regulations in many countries, limiting global expansion.
- High competition in the medical cannabis sector may reduce market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.